alexa 10 Years Securely Hosting Collaborative Drug Discovery CDD Vault In A Single, Privately Managed "cloud"
ISSN: 2161-0444

Medicinal chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference on Medicinal Chemistry & Computer Aided Drug Designing
December 08-10, 2014 DoubleTree by Hilton Hotel San Francisco Airport, USA

Barry Bunin
Accepted Abstracts: Med Chem
DOI: 10.4172/2161-0444.S1.013
Drug Discovery Collaborations have been securely hosted in the CDD Vault since before "The Cloud" was part of our everyday vocabulary. A decade of experience provides unique insights to make individual drug discovery collaborations, and complex collaborations economically scale. Layering unique collaborative capabilities upon sophisticated drug discovery informatics functionality unlocks and amplifies synergy between biologists and chemists. In addition to intuitive registration, structure activity relationship tools, and secure collaboration tools, CDD has given back to the community public data sets (in CDD Public and Pubchem), Open Source Descriptors and Models (in GitHub and CDK toolkits), and via free mobile applications (TB Mobile). Researchers need to have tools that balance individual needs for robust, intuitive registration and bioactivity analyses while at the same time facilitating collaborations with secure data partitioning, communication, and group engagement. Collaborative technologies have crossed the chasm from academic, neglected disease to mainstream commercial drug discovery applications. Since collaborative technology is "therapeutic area agnostic", it has generally been proven equally applicable for commercial applications. Representative commercial case studies include broad consortia such as the NIH Neuroscience Blueprint collaboration between drug discovery companies, CROs, together with seven leading academic biology laboratories as part of a 5-year government contract to advance new CNS drugs into the clinic. As well as more focused examples following the lean venture funded model such as the collaboration between Acetyton Pharmaceuticals with Harvard and a Chinese CRO to bring a selective HDAC inhibitor into the clinic. Collaborative innovation allows well-integrated specialization required for drug discovery both within and between laboratories. Particularly for collaborations between large and small companies or between industry and academia - superior collaborative tools are fundamentally important to catalyze faster progress. In summary, by spanning the continuum of private, collaborative and public modes, researchers globally can now seamlessly collaborate across the pre-competitive and competitive landscape.
Barry A Bunin, PhD, is the CEO of Collaborative Drug Discovery. Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. He is on a patent for Kyprolis? (carfilzomib) for Injection, a proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma. He was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, he led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry). On the scientific side, he co-authored ?Chemoinformatics: Theory, Practice, and Products? (Springer- Verlag), a text that overviews modern chemoinformatics technologies, and ?The Combinatorial Index? (Academic Press), a widely used text on high-throughput chemical synthesis. In the lab, he did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. He received his BA from Columbia University and his PhD from UC Berkeley, where he synthesized and tested the initial 1, 4-benzodiazepine libraries with Professor Jonathan Ellman.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version